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Background: Tangier disease (TD) is a phenotypic expression of rare familial syndrome with mutations in the
ABCA1 transporter. The risk of coronary artery disease in patients with TD is variable. On the other hand the pivotal
role of Platelet-Activating Factor (PAF) mediator in atheromatosis was found. Plasma lipoproteins are transporters of
the PAF acetylhydrolase (PAF-AH) in cells and known as lipoprotein-phospholipase A2 (Lp-PLA2) in plasma and
regulators of PAF levels in blood. In addition, PAF can be biosynthesized from the remodeling and the de novo
pathways in which Lyso-platelet activating factor-acetyltransferase (Lyso-PAF-AT) and platelet activating
factor-cholinephosphotransferase (PAF-CPT) are the regulatory enzymes. The aim of this study is to investigate in a
TD patient with a unique mutation (C2033A), the concentration of PAF in blood, the Equivalent Concentration for
50% aggregation (EC50) values of platelet rich plasma (PRP) toward PAF, adenosine diphosphate (ADP) and
thrombin, and the activities of PAF metabolic enzymes Lp-PLA2, PAF-AH, Lyso-PAF-AT and PAF-CPT.
Methods: The EC50 value of PRP was measured by an aggregometer. The determination of the specific activity of
PAF-CPT and Lyso-PAF-AT was made after in vitro enzymatic assay, chromatographic separation and measurement
of the produced PAF in a biological assay with washed rabbit platelets. The determination of PAF-AH and Lp-PLA2
was made after an in vitro enzymatic assay from the decay of radioactive PAF.
Results: The TD patient had lower bound-PAF values in blood, decreased specific activity of PAF-CPT and
Lyso-PAF-AT, increased specific activity of PAF-AH in platelets and leukocytes and Lp-PLA2 activity in plasma
compared to healthy women. The EC50 of PAF and Thrombin were higher compared to healthy women.
Conclusion: The increased Lp-PLA2 activity, as well as, the decreased activities of PAF-CPT and Lyso-PAF-AT, explain
the decreased bound-PAF level in TD patient and the EC50 of PAF. However, total PAF is in a normal range and this
probably can explain one of the reasons this TD patient has no CAD.
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Tangier disease (TD) is a rare genetic disorder that was
first described by Fredrickson et al. [1] and it is charac-
terized by nearly absence of high density lipoprotein
(HDL) cholesterol in patients’ plasma. Only recently, in
1999, has been reported that mutations in the ATP bind-
ing cassette A1 transporter (ABCA1) is responsible for
TD [2-4].* Correspondence: bkolovou@gmail.com
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reproduction in any medium, provided the orABCA1 is a member of the ABCA subfamily with high
expression levels in hepatocytes, adrenal glands, liver,
lung and several other tissues [5,6]. In vivo models with
ABCA1 inactivation demonstrated cholesterol depos-
ition in macrophages and other cells [7], suggesting a
pivotal role of this transporter in the trafficking of lipids,
HDL biogenesis, and overall cholesterol homeostasis.
Approximately, 1/3 of TD patients may develop coronary
artery disease (CAD) [8]. The mechanism of CAD in TD
patients is still not very clear. Several mechanisms, beside
lipid metabolism, may be involved in the development of
CAD. Inflammation is the one of these mechanisms. The
inflammation is initiated by leukocytes and lipoproteinsl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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undergo oxidation (2) and the monocyte-derived macro-
phages after digestion of modified lipoprotein particles form
foam cells [9]. Macrophages, after their activation,
synthesize proinflammatory and prothrombotic factors
such as platelet-activating factor (PAF) [10] which is a
powerful mediator of inflammation [11] and a key factor
for atherosclerosis [12]. A pathological regulation of PAF
metabolism results in increased PAF-levels and triggers
local inflammatory response of vascular endothelium [12].
PAF biosynthesis is regulated by two different enzym-
atic pathways: the de novo pathway in which the key en-
zyme is specific dithiothreitol-insensitive CDP-choline:
1 -alkyl -2-acetyl-sn-glycerolcholinephosphotransferase
(PAF- cholinephosphotransferase, PAF-CPT, EC 2.7.8.16)
that converts 1-O-alkyl-2-acetyl-glycerol to PAF; and the
remodeling one in which the key enzyme is Lyso-PAF:
acetyl-CoA acetyltransferase (Lyso-PAF-acetyltransferase,
Lyso-PAF-AT, EC 2.3.1.67) [13] which acetylates Lyso-
PAF. It is believed that the de novo reaction sequence
appears to be responsible for its constitutive synthesis
maintaining resting PAF levels in various tissues and
blood whereas the remodeling route plays a crucial role in
inflammatory/hypersensitivity responses of PAF.
PAF is catabolized by PAF-acetylhydrolase (PAF-AH,
EC 3.1.1.47). PAF-AH has an isoform in plasma,
also known as lipoprotein-associated phospholipase A2
(Lp-PLA2) [14]. PAF-AH action is to cleave short chain
acyl chains at the sn-2 position of phospholipids [14]
such as oxidized phospholipids and PAF [10]. Since
PAF-AH cleaves PAF (which is an atherogenic factor) it
can be characterized as an anti-atherogenic enzyme [15].
In the present study, we determined in a TD patient
the specific activities of PAF anabolic enzymes (PAF-
CPT and Lyso-PAF-AT) in platelets and leukocytes as
well as the specific activity of the catabolic enzyme PAF-
AH in the same set of cells and erythrocytes along with
the activity of Lp-PLA2 in plasma. We measured PAF
levels (free, bound and total) in blood and we studied
the EC50 values of PAF, thrombin and adenosine diphos-
phate (ADP) in Platelet-Rich Plasma (PRP).
Patients and methods
Patient with TD
We studied a 43 years old Greek women with TD, previ-
ously described by Kolovou et al. [16]. The patient had no
CAD documented angiographically [17] and had no signs
of carotid artery atherosclerosis as evaluated by echocardi-
ography. At the present time she was an ex-smoker. She is
the child of two second-degree cousins and a mother of
three girls. Clinical examination revealed mild hepatosple-
nomegaly. Blood samples were performed in the 21st day
of her menstrual cycle and the lipid measurements were
made in the same day. No enlarged tonsils, pathologicallymph nodes, peripheral neuropathy or atherosclerosis
were present. Her lipid profile was typical of TD pheno-
type. DNA analysis has revealed a new mutation
(C2033A) in both alleles, causing a premature stop codon
at the amino acid residue 573, which resulted in trunca-
tion of the ABCA1 protein [18].
Control group
The control group consisted of 12 women aged
64 ± 10 years old who were self-reported as healthy.
The Department of Chemistry of National and Kapodis-
trian University of Athens and Onassis Cardiac Surgery
Center ethics committee approved the protocol of this
study. All subjects signed an informed consent form.
Isolation of human PRP and PPP (platelet poor plasma) for
the determination of EC50 values
Human blood, collected from an antecubital vein, was
distributed into 2 polyethylene tubes containing anti-
coagulant (0.1 M buffered dextrose citrate, ACD) in the
ratio of blood/anticoagulant: 9/1 (v/v) to a final volume
of 10 mL. The isolation of PRP was performed as previ-
ously described [19,20]. Briefly, the PRP was obtained by
centrifugation (1st) of blood specimens at 194 × g for
10 min. PRP was then transferred to polypropylene tubes
at room temperature for the biological assay, whereas
PPP was obtained by further centrifuging (2nd) the spe-
cimens at 1465 × g for 20 min. PRP was adjusted to
500000 platelets/μL using the respective PPP. All proce-
dures took place at 24 °C (room temperature).
Isolation of human plasma, platelets, erythrocytes and
leukocytes
The isolation was performed as previously described [21].
Briefly, human blood, collected from an antecubital vein
was distributed into 1 polyethylene tube containing anti-
coagulant in the ratio of blood/anticoagulant: 9/1, so as
the total volume in each tube to be 10 mL. The procedure
is the same as above but after the 2nd centrifugation
(1465× g, 20 min) the supernatant (plasma) was collected,
aliquoted and stored at -80°C. In the pellet from the 2nd
centrifugation 1 mL of a buffer containing 50 mM Tris–
HCl (pH 7.4) was added and was sonicated 4× 15 s in an
ice bath, the sample was then centrifuged (3rd) at 500× g
for 10 min at 4°C. The supernatant was the platelets hom-
ogenate which was aliquoted and stored at -80°C. In the
pellet of the 1st centrifugation saline to a final volume of
10 mL was added. After mildly redissolving, 3.4 mL of
dextran solution was added (3% dextran in NaCl 0.15 M)
to induce erythrocyte sedimentation. The mixture was
kept for 1 hour at room temperature and the leukocyte-
rich supernatant (LRP) was then centrifuged (4th) at
500× g for 10 min at room temperature. The remaining
erythrocytes in the sediment were lysed with the addition
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10 mM KHCO3, and 0.1 mM EDTA, and after 5 min
removed by centrifugation (5th) at 300× g for 10 min at
room temperature. The pelleted cells (leukocytes) were
resuspended in 1 mL of a buffer containing 50 mM Tris–
HCl (pH 7.4) and then sonicated into ice for 4× 15 s. After
a centrifugation (6th) at 500× g for 10 min at 4°C the
supernantant of washed human leukocytes (WHLs) hom-
ogenate was aliquoted and stored at -80°C. From the sedi-
ment of erythrocytes a volume of 500 μL was added in
2.5 mL of saline and then centrifuged (7th) at 200× g for
10 min at room temperature. The pellet was resuspended
in 2 mL of a buffer containing 50 mM Tris–HCl (pH 7.4)
and centrifuged at 500× g for 10 min at 4°C. The super-
natant was aliquoted and stored at -80°C.
Human PRP aggregation studies
Human PRP was obtained as previously described. Ali-
quots of PAF solution in chloroform/methanol (1:1 v/v)
were evaporated under a stream of nitrogen and were
redissolved in BSA (1.25% in saline) to obtain PAF solu-
tions with final concentrations into cuvette ranging from
1.0 10–8 to 1.0 10–5 mol/L. ADP and Thrombin were
dissolved in saline to obtain solutions with final concen-
trations into cuvette ranging from 10-10 to 10-9 M of
ADP and 90 to 370 U/L of Thrombin, respectively. The
maximum reversible or the minimum irreversible PAF-
induced platelet aggregation was determined as the
100% aggregation, and then various PAF concentrations
were added, so as to achieve aggregations between 20%
and 80%. These PAF-induced aggregations were of linear
response to the respective PAF concentration; therefore,
the EC50 value was calculated. EC50 (Equivalent Concen-
tration for 50% aggregation) accounts for the aggregating
agent concentration inducing 50% aggregation [21,22]
and results are expressed as M or Units (final concentra-
tion in the cuvette).
PAF isolation and purification
The isolation and purification of PAF was according to
the method of Demopoulos et al. [23]. Briefly, 10 mL of
blood were collected from each human subject and
poured immediately (after collection) into 40 mL of ab-
solute ethanol. The mixture was stirred and centrifuged
at 300 × g for 10 min. The supernatant and the pellet
were extracted separately according to the Bligh and
Dyer method [24] and the chloroform phase in each case
was stored. The supernatant chloroform extract contains
plasma PAF, named as free PAF, while the pellet extract
contains cell–PAF, named as bound PAF. The above
extracts were purified on silicic acid column chromatog-
raphy that was eluted with 45 mL of methanol/water
(1:1.5, v/v), followed by 50 mL of methanol/water (2:1,
v/v). The initial 45 mL (containing the bulk ofproteinaceous and other non-lipid impurities) were dis-
carded while the PAF containing eluents were further
purified by HPLC on a cation-exchange column. The
solvent system consisted of an isocratic elution of aceto-
nitrile/methanol/water (61:31:8, v/v/v) slightly modified
from the one described in [23]. The eluted substances
were detected using UV detection at 208 nm.
Washed rabbit platelet aggregation
Washed rabbit platelets were prepared as previously
described [10]. PAF and the all examined samples were
dissolved in BSA 1.25% in saline. The PAF concentration
of the samples was estimated against an 8 point regres-
sion curve of standard PAF. The study was performed
using a Chronolog aggregometer (model 400) (Haver-
town, Pa, USA) at 37°C with constant stirring at
1200 rpm, coupled to a Chronolog recorder.
PAF-AH activity assay
The PAF-AH enzymatic assay was performed as previ-
ously described [25]. Briefly, Tris–HCl 50 mM pH 7.4
buffer was mixed with 4 nmol of [3H]-PAF (20 Bq per
nmol)/PAF solution in BSA (1% in saline). The whole
mixture was incubated at 37°C for 5 min and the reac-
tion was initiated by adding homogenates (0.25 mg/mL
for leukocytes, 0.5 mg/mL for platelets and 2.5 mg/mL
for erythrocytes at final volume of 200μL). The reaction
took place at 37°C for 30 min and was stopped by the
addition of BSA solution (final concentration 0.75 mg/
mL) and followed by precipitation with trichloroacetic
acid (TCA; final concentration 9.6% v/v). The mixture
stayed in ice bath for 30 min and then was centrifuged
at 16000 × g for 5 min at 4°C. The [3H]-acetate released
from the reaction was measured on the liquid scintilla-
tion counter by placing 0.1 mL of the suspension liquid
into 5.0 mL of scintillation liquid. The enzyme activity
was expressed as pmol of PAF degraded per minute per
mg total protein except of the fraction of plasma where
the enzyme activity was expressed as pmol of PAF
degraded per min per μL of plasma. All experiments
were conducted in triplicates.
Dithiothreitol-insensitive PAF-CPT activity assay
Assay was performed at 37°C for 20 min in a final vol-
ume of 200 mL containing 0.05 mg/mL protein,
100 mM Tris–HCl (pH 8.0), 15 mM DTT, 0.5 mM ethy-
lenediaminetetraacetic acid (EDTA), 20 mM MgCl2,
1 mg/mL BSA, 100 μM Cytidinediphosphocholine
(CDP-Choline), and 100 μM AAG. The reaction was
stopped by adding 500 μL of methanol. The assay pro-
cedure, extraction, purification, and determination of
produced PAF concentration were performed as previ-
ously described [26]. The enzyme activity was expressed
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protein. All experiments were conducted in triplicates.Lyso PAF-AT activity assay
Assay was performed as previously described [20].
Briefly, the reaction was carried out at 37°C for 30 min-
utes in a final volume of 200 μL containing 0.125 mg/
mL protein, 50 mM Tris–HCl (pH 7.4), 0.25 mg/mL
BSA, 20 μmol/L Lyso-PAF, and 200 μmol/L acetyl-CoA.
The reaction was stopped by adding 500 μL of methanol
and the extraction, purification, and determination of
PAF was carried out as mentioned in the PAF-CPT assay
[26]. The enzyme activity was expressed as pmol of
synthesized PAF per min per mg of total protein. All
experiments were conducted in triplicates.Statistical analysis
The Wilcoxon non parametric statistic analysis for one
sample was performed to compare the sample of TD pa-
tient with 12 healthy women. The statistic significance
was established at 5% (p < 0.05) and the variables of con-
trol group are shown as median and percentiles (25% –
75%).Results
The patient’s lipid profile was typical for TD (Table 1).
Patient’s “free” PAF was 4.74 fmol/mL and “bound”
PAF was 1.32 fmol/mL giving a total PAF of 6.06 fmol/
mL. In the control group “free” PAF was 3.16 fmol/mL
(1.89-12.86) and “bound” PAF was 2.92 fmol/mL (2.27-
3.99), so the total PAF was 6.40 fmol/mL (3.92-16.31)
(Figure 1).
Many studies expressed the PAF levels in pg/mL and
for this reason we converted our results from fmol/mL
to pg/mL. After conversion with a theoretical molecular
weight of PAF at 548 pg/mol, “free” PAF was 2.60 pg/mL
and 1.73 pg/mL, “bound” PAF was 0.72 pg/mL and
1.60 pg/mL, and total PAF was 3.32 pg/mL and 3.50 pg/
mL, in TD patient and control group, respectively.Table 1 Lipid profile and the biochemical measurements
of the TD patient
TD patient Desirable range
Total cholesterol 88 mg/dL <200 mg/dL
Triglycerides 100 mg/dL <150 mg/dL
HDL-cholesterol 2 mg/dL >40 mg/dL
LDL-cholesterol 66 mg/dL <130 mg/dL
Leukocytes number 4.8 K/μL 4.0-10 K/μL
Erythrocytes number 4.6 M/μL 3.9-4.9 M/μL
Platelets 117 K/μL 150-400 K/μL
HDL-cholesterol: High density lipoprotein-cholesterol.
LDL-cholesterol: Low density lipoprotein cholesterol.The Lp-PLA2 activity was 37.12 pmol/min/μL in the
TD patient, while in the control group was 22.25 pmol/
min/μL (17.40-25.01) (p < 0.05) (Figure 2). The specific
activity of PAF-AH in the TD patient’s leukocytes, ery-
throcytes and platelets was 77.56, 9.01 and 821.41 in
pmol/min/mg of protein, respectively while in healthy
women the corresponding activities were 6.60 (2.14-
15.48), 17.26 (13.08-19.91), and 14.19 (11.74-17.92)
(p < 0.05) (Figure 3). The activity of Lyso-PAF-AT in leu-
kocytes and platelets was 5.52 and 0.37 pmol/min/mg of
protein respectively, in the TD patient. In the control
women the Lyso-PAF-AT specific activity in leukocytes
was 20.31 (4.05-44.15) and in platelets was 9.18 (3.61-
11.41) pmol/min/mg (p < 0.05) (Figure 4). PAF-CPT spe-
cific activity in leukocytes and platelets was 45.29 and
5.61 pmol/min/mg of protein, respectively, while in the
control women’s leukocytes was 43.54 (33.88-121.14)
and in platelets was 252.93 (212.36-282.48) pmol/min/
mg (p < 0.05) (Figure 5).
The patient’s EC50 value of the aggregation in PRP of
PAF was 36.510-7 M, of ADP was 20.1510-10 M and of
Thrombin was 183U/L (final concentration in the cu-
vette). In control group the EC50 of PAF was 9.510-7 (5-
17) M, of ADP 12610-10 (111-165) M and of thrombin
17 (12-20) U/L (Figures 6, 7 and 8).
Discussion
PAF levels
This is the first time that PAF levels were measured in
blood sample of TD patient. Although, the bound PAF
values of TD patient were lower in comparison with the
control group, the total PAF values were in the normal
range. Chen et al. [27] evaluated the PAF in nonsmoking
patients with periodontits and/or CAD and found differ-
ent values compared to our study. Also, different PAF
values were found in few other studies evaluated patients
with periodontal disease [28,29], asthma [30], anaphyl-
axis [31], heart failure [32] and liver cirrhosis [33]. In all
of these studies the PAF values were higher compared to
controls. The discrepancy found between our study and
others investigators can be explained that we performed
measurements with different method and the disease
was different.
Lp-PLA2, PAF-AH, Lyso-PAF-AT, PAF-CPT
This is the first study which evaluated the specific activ-
ities of PAF-AH, Lyso-PAF-AT, PAF-CPT and the activ-
ity of Lp-PLA2, in a TD patient. However, Pritchard
et al. [34] and Stafforini et al. [35] have evaluated solely
the Lp-PLA2 activity in patient with TD. Both studies
found that the activity of Lp-PLA2 was higher in patients
than controls. The values of the activities of Lp-PLA2,
similar to PAF, differ among studies. This happens be-
cause the evaluated variables are measured in different
Figure 1 Levels of Free-PAF, Bound-PAF and total PAF in blood of the control group and TD patient. The box plots indicate the data
from the control group while the single bar indicates the mean (and also median) value of TD patient. (†: statistically significant difference
compared to control group, p < 0.05).
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pathological situations, such as acute coronary syndrome
and unstable angina [9], polycystic ovary syndrome [36],
heart failure [32], human immunodeficiency virus (HIV)
infection and acquired immunodeficiency syndrome
(AIDS) [37], CAD patients after positive exercise test
[38] and hypertension [39], the Lp-PLA2 activity was
increased compared with controls.Figure 2 The activity of Lipoprotein-phospholipase A2 (Lp-PLA2) in pl
data from the control group while the single bar indicates the mean (and
compared to control group, p < 0.05).A number of studies evaluating the activity of Lp-PLA2 in
various pathological situations found lower values com-
pared with control group. Vadas et al. [31] measured the ac-
tivity of Lp-PLA2 in patients with anaphylaxis and found
lower specific activity than in control group and PAF values
of 805±595 pg/mL in patients and 127±104 pg/mL in
controls. Similar results were reported by Rufail et al. [40]
in patients with generalized aggressive periodontitis andasma in TD patient and in control group. The box plots indicate the
also median) value of TD patient. (†: statistically significant difference
Figure 3 The specific activity of PAF-acetylhydrolase (PAF-AH) in cells in TD patient and in control group. The box plots indicate the data
from the control group while the single bar indicates the mean (and also median) value of TD patient. (†: statistically significant difference
compared to control group, p < 0.05).
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fore and after treatment. In addition, Serebruany et al. [42]
measured plasma levels of PAF-AH and found that in
patients with acute myocardial infarction were significantly
lower comared with controls.
In our study the patient’s specific activities of PAF-AH
in platelets and leukocytes and the activity of Lp-PLA2Figure 4 The specific activity of Lyso-PAF-acelyltransferase (Lyso-PAF
indicate the data from the control group while the single bar indicates the
difference compared to control group, p < 0.05).in plasma, were increased compared to healthy women
(p < 0.05). The patient’s specific activities of PAF-CPT in
platelets and Lyso-PAF-AT in platelets and leukocytes,
were decreased compared to healthy women (p < 0.05).
The decreased specific activities of PAF-CPT and Lyso-
PAF-AT also indicate the lack of a chronic or an acute
inflammation.-AT) in cells, in TD patient and in control group. The box plots
mean (and also median) value of TD patient. (†: statistically significant
Figure 5 The specific activity of PAF-cholinephosphotransferase (PAF-CPT) in cells, in TD patient and in control group. The box plots
indicate the data from the control group while the single bar indicates the mean (and also median) value of TD patient. (†: statistically significant
difference compared to control group, p < 0.05).
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It is the first time that EC50 of the aggregation in TD
patient’s PRP of PAF, ADP and thrombin are measured.
Stathopoulou et al. [43] found in 69 healthy individuals
that the PAF EC50 values ranged 0.13-24.37 10
-7 M. In
addition, Goudevenos et al. [38] studied platelet re-
sponse to the aggregatory effect of PAF in 44 patientsFigure 6 The EC50 of PAF in platelet rich plasma (PRP) in TD patient a
control group while the single bar indicates the mean (and also median) v
control group, p < 0.05).with CAD who performed exercise tests. The PAF EC50
values in 21 patients with positive exercise test were
found to be significantly decreased at rest compared
with 21 subjects with negative exercise test.
In our study the patient’s EC50 of PAF was increased com-
pared to healthy women (p<0.05), which can be explained
by the increased activity of Lp-PLA2. The patient’s EC50nd in control group. The box plots indicate the data from the
alue of TD patient. (†: statistically significant difference compared to
Figure 7 The EC50 of ADP in platelet rich plasma (PRP) in TD patient and in control group. The box plots indicate the data from the
control group while the single bar indicates the mean (and also median) value of TD patient. (†: statistically significant difference compared to
control group, p < 0.05).
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compared to healthy women (p<0.05).
Tselepis et al. [44] studied platelet aggregation in the
PRP of 32 patients with unstable angina before and after
treatment with abciximab. The PAF EC50 values were
significantly lower on the day of admission, whereas the
maximal percentage of aggregation was significantlyFigure 8 The EC50 of Thrombin in platelet rich plasma (PRP) in TD pa
control group while the single bar indicates the mean (and also median) v
control group, p < 0.05).higher compared to controls. Similar behavior of the pla-
telets was observed in the aggregatory effect of ADP.
Also, Demopoulos et al. [45] found that ADP (5 μM)
caused decreased or normal platelet aggregation in the
homozygous beta-thalassaemic patients, approximately
normal in the heterozygous subjects and increased in
the splenectomized patients.tient and in control group. The box plots indicate the data from the
alue of TD patient. (†: statistically significant difference compared to
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elevated in TD patients but with lower responsiveness at
lower thrombin concentrations and they suggested that
platelets were less responsive to thrombin than in nor-
mal control subjects. We found higher value of EC50 of
thrombin in TD patient compared with controls and we
can assume that some co-enzymes could be in lower
concentrations or less active in PRP of TD patient.
The reason why our TD patient has not developed
foam cells and CAD is unknown and was extensively
discussed by Kolovou et al. [17]. Furthermore, it may be
partially explained by PAF metabolism. Since, PAF play
an important role in atherosclerosis the development of
CAD may depend on PAF levels in blood, as well as, bio-
synthesis and catabolism of PAF in cells.
In conclusion, the biosynthetic enzymes (PAF-CPT
and Lyso-PAF-AT) of TD patient have lower specific ac-
tivity than of the control group, which can be explained
by the decreased levels of PAF. The catabolic enzyme
PAF-AH specific activity in leukocytes, in platelets and
Lp-PLA2 activity in plasma is higher in TD patient than
in controls. Opposite, the PAF-AH in erythrocytes was
lower than in control group.
Thus, this may partially explain why bound PAF levels
are lower in TD patient compared with normal subjects.
The measurements of total PAF levels which were close
to the normal range, may be the reason for not develop-
ing CAD in TD patients.
Limitations
It is hard to establish whether the features observed with
this TD patient are similar in other TD patients, since
TD is a rare genetic disease with approximately 50
indentified cases all over the world. In addition, this is
the first time that PAF metabolism, as well as, PAF levels
and aggregability, were measured in a TD patient.
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